Modality
Cell Therapy
MOA
FcRni
Target
GPRC5D
Pathway
Innate Imm
ASFTD
Development Pipeline
Preclinical
Aug 2022
→ Dec 2027
PreclinicalCurrent
NCT04624799
1,973 pts·AS
2022-08→2027-12·Active
1,973 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-201.7y awayInterim· AS
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2027-12-20 · 1.7y away
AS
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04624799 | Preclinical | AS | Active | 1973 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D |